Abstract
Background and Aims
The current use of Health Technology Assessment (HTA) as a supporting tool for decision-making still varies considerably across different healthcare systems in Europe thus resulting in inefficiency of actual reporting of HTA. The new H2020 project, HTx (htx-h2020.eu) aims to develop a framework for next generation HTA that supports patient-centred, societally-oriented, real-time decision-making for integrated healthcare. Four different case studies will be performed to cover different types of disease areas, technologies and treatment strategies, one of them is focused on T1DM and T2DM.
Methods
HTx proposes the use of methods to bring together data from different sources such as Randomized Controlled Trials (RCT) and real-world data (RWD) with classical prediction modelling and artificial intelligence algorithms to integrate existing evidence and estimate relative clinical effectiveness and cost-effectiveness in complicated treatment and monitoring pathways.
Results
In T1DM and T2DM, the expected results are to assess the impact of using medical devices such as insulin infusion pumps, continuous glucose monitoring and glucose meters, e-health technologies such as tele-monitoring complemented by data visualization and decision support; and/or life-style interventions. We will link data from RCTs on these technologies to large population-based diabetes registries and health care claims data.
Conclusions
HTx should be able to provide more accurate estimations of the differential health impact of the technologies in specific subgroups of patients with Diabetes; predict which treatments combinations are most beneficial and cost-effective and facilitate tools that support patients and their healthcare providers in making personal decisions on the best treatment.
